natgillin/translations-raw huggingface dataset:
It should be noted that in the majority of these reports tuberculosis was extrapulmonary, presenting as either local or disseminated disease.
Treba pa je poudariti, da so pri večini teh bolnikov tuberkulozo ugotovili zunaj pljuč in je šlo bodisi za lokalno ali diseminirano bolezen.
It should be noted that in the majority of these reports, tuberculosis was extrapulmonary presenting as either local or disseminated disease.
Poudariti je treba, da je bila pri večini teh poročil tuberkuloza zunaj pljuč in je nastopila bodisi v obliki lokalne ali diseminirane bolezni.
It should be noted that patients using beta-blockers do not necessarily respond to the beta-agonists usually used for the treatment of hypersensitivity reactions.
Treba je biti pozoren na to, da ni nujno, da se bolniki, ki uporabljajo beta-blokatorje, odzovejo na betaagoniste, ki se po navadi uporabljajo pri zdravljenju preobčutljivostnih reakcij.
It should be noted that patients using beta-blockers do not necessarily respond to the beta-agonists usually used for the treatment of hypersensitivity reactions.
Treba je biti pozoren na to, da ni nujno, da se bolniki, ki uporabljajo blokatorje beta, odzovejo na agoniste beta, ki se po navadi uporabljajo pri zdravljenju preobčutljivostnih reakcij.
It should be noted that patients with factor IX inhibitors may be at an increased risk of anaphylaxis with subsequent challenge with factor IX.
Upoštevati moramo tudi, da imajo lahko bolniki z inhibitorji faktorja IX povišano tveganje za anafilaksijo ob kasnejši izpostavitvi faktorju IX.
It should be noted that the relationship between sirolimus trough concentration and AUC is changed during co- administration with posaconazole.
Zavedati se je treba, da se med sočasno uporabo sirolimusa in posakonazola spremeni razmerje med najnižjo koncentracijo sirolimusa in njegovo AUC.
It should be noted that the side effects may be intensified.
Zavedati se je treba, da se neželeni učinki lahko stopnjujejo.
It should be noted that there was no dose-finding study in mucormycosis, and patients were administered the same dose of isavuconazole as was used for the treatment of invasive aspergillosis.
Vedeti je treba, da ni bilo študij za ugotovitev odmerka pri zigomikozi in bolniki so prejeli enak odmerek izavukonazola, kot so ga uporabili za zdravljenje invazivne aspergiloze.
It should be prescribed only to patients aged 12 years and above confirmed to have the F508del mutation in both copies of the CFTR gene.
Predpisovati se sme le bolnikom, starejšim od 12 let, ki imajo potrjeno mutacijo F508del v obeh kopijah gena CFTR.
It should be recognised that daratumumab bound to RBCs may mask detection of antibodies to minor antigens in the patient’s serum.
Treba je vedeti, da na eritrocite vezani daratumumab lahko moti določanje protiteles proti manjšim antigenom v bolnikovem serumu.
It should be taken either in combination with aspirin or together with aspirin and clopidogrel or aspirin and ticlopidine.
Vzeti ga je treba v kombinaciji z aspirinom ali skupaj z aspirinom in klopidogrelom oz. aspirinom in tiklopidinom.
It should be taken into account that data for the once daily regimen are very limited in this population (see sections 5.1 and 5.2).
Treba je upoštevati, da so podatki o enkrat dnevnem režimu odmerjanja za to populacijo omejeni (glejte poglavje 5.1 in 5.2).
It should be taken into account that some people feel dizzy and sleepy after taking EMEND.
Upoštevati je treba, da nekateri ljudje po zaužitju zdravila EMEND postanejo omotični in zaspani.
It should be taken into account that some people get dizzy and get sleepy after using IVEMEND.
Upoštevati morate, da se pri posameznih bolnikih po zdravljenju z zdravilom IVEMEND lahko pojavita omotica ali zaspanost.
It should be taken into account that some people may feel dizzy and sleepy after taking EMEND.
Upoštevati je treba, da lahko nekateri ljudje po zaužitju zdravila EMEND postanejo omotični in zaspani.
It should be taken into account that some people may get dizzy after receiving BRINAVESS, usually within the first two hours (see section “Possible side effects”).
Upoštevati je treba, da se lahko pri nekaterih osebah po prejetju zdravila BRINAVESS pojavi omotica, običajno se pojavi v prvih dveh urah (glejte poglavje "Možni neželeni učinki ").
It should be taken into account that these conditions may recur or be aggravated during treatment with DUAVIVE, in particular:
Treba je upoštevati, da se med zdravljenjem z zdravilom DUAVIVE ta bolezenska stanja lahko ponovijo ali poslabšajo, zlasti:
It should be taken twice daily in the morning and in the evening, in two equally divided doses.
Jemlje se dvakrat na dan, zjutraj in zvečer, razdeljen na dva enaka odmerka.
It should be taken twice daily with water in the morning and in the evening, in two equally divided doses.
Jemati ga je treba dvakrat na dan z vodo, zjutraj in zvečer, v dveh enakih odmerkih.
It should be taken with a light meal preferably at the same time each day, but grapefruit juice should not be taken together with Sprimeo
Vzeti ga je treba z lahkim obrokom, najbolje vsak dan ob istem času, vendar pa se zdravilo Sprimeo HCT ne sme vzeti skupaj s sokom
It should be taken with food.
Jemati ga je treba s hrano.
It should be used after careful evaluation of alternative treatment options.
Uporabi se lahko po skrbni oceni nadomestnih možnosti zdravljenja.
It should be used in combination with safer sex practices, such as use of condoms.
Uporabljati bi ga bilo treba v kombinaciji z varnejšimi spolnimi praksami, na primer uporabo kondomov.
It should be used with caution in ACS patients:
Zdravilo je treba previdno uporabljati pri bolnikih z AKS, ki:
It should be used within 6 hours (including the one hour infusion intravenous administration).
Porabiti jo je treba v 6 urah (ena ura infundiranja všteta).
It should not be administered in a line containing dextrose.
Ne smemo ga injicirati v venski kanal, v katerem je dekstroza.
It should not be punctured, broken or burnt, even when apparently empty.
Vsebnika ne prebadajte, prelamljajte in ne sežigajte, tudi če je na videz prazen.
It should not be shaken vigorously.
Viale ne smete močno stresati.
It should not be used for the treatment of patients with mild or moderate asthma or for the initiation of treatment for patients with severe asthma unless the requirement for such a high dose of the corticosteroid together with a long-acting β2 agonist has been established previously.
Ne sme se ga uporabljati za zdravljenje bolnikov z blago ali zmerno astmo ali za uvedbo zdravljenja pri bolnikih s hudo astmo, razen če je bilo predhodno ugotovljeno, da je tako velik odmerek kortikosteroida skupaj z dolgodelujočim agonistom β2 potreben.
It should not be used if immune- mediated thrombocytopenia from structurally related active substances including quinine and mefloquine is suspected, as cross-sensitivity can occur.
Zdravilo se ne sme uporabiti, če obstaja sum na imunsko trombocitopenijo, ki je posledica strukturno sorodnih zdravilnih učinkovin, vključno s kininom in meflokinom, saj se lahko pojavi navzkrižna občutljivost.
It should not be used in patients who have certain problems with their liver or severe kidney problems.
Zdravilo se ne sme uporabljati pri bolnikih, ki imajo
It should not be used in pregnant women.
Ne sme se ga uporabljati pri nosečnicah.
It should not be used in women who have migraine with aura (visual or other symptoms), some types of cancer or abnormal bleeding from the genital area whose cause has not been diagnosed.
Zdravila ne smejo uporabljati ženske, ki imajo migreno z avro (očesnimi ali drugimi simptomi), ženske z nekaterimi vrstami raka ali nenormalnimi krvavitvami iz področja genitalij, katerih vzrok še ni bil ugotovljen.
It should not be used to relieve a sudden attack of breathlessness or wheezing.
Zdravila Relvar Ellipta se ne sme uporabljati za olajšanje nenadnega napada težkega dihanja ali piskanja.
It should not be used to relieve a sudden attack of breathlessness or wheezing.
Zdravila Revinty Ellipta se ne sme uporabljati za olajšanje nenadnega napada težkega dihanja ali piskanja.
It should not be used to treat nausea and vomiting following chemotherapy.
Ne smemo ga uporabljati za zdravljenje navzee in bruhanja po kemoterapiji.
It should not be used when a woman has, or has had, venous or arterial thrombosis (blood clots in the veins or arteries) including a stroke or a heart attack or when a woman has some of the risk factors for thrombosis (severe high blood pressure, diabetes with damage to the blood vessels, high cholesterol levels, or a family history of thrombosis).
Prav tako ga ne smejo uporabljati ženske, ki imajo ali so imele vensko ali arterijsko trombozo (krvne strdke v venah ali arterijah), vključno s kapjo ali srčnim napadom, ali ženske z dejavniki tveganja za pojav tromboze (močno povišan krvni tlak, sladkorna bolezen s poškodbami krvnih žil, visoke ravni holesterola ali družinska anamneza tromboze).
It should not be used with combinations that are ‘modified release’ (when the levodopa is released slowly over a few hours).
Ne sme se ga uporabljati skupaj v kombinacijah s „prilagojenim sproščanjem“ (kjer se levodopa počasi sprošča v obdobju več ur).
It should not be used with combinations that are ‘modified release’ (when the levodopa is released slowly over a few hours).
Ne sme se ga uporabljati v kombinacijah s „prilagojenim sproščanjem“ (kjer se levodopa počasi sprošča v obdobju več ur).
It should not be used with combinations that are ‘modified release’ (when the levodopa is released slowly over a few hours).
Ne sme se uporabljati s kombinacijami s prirejenim sproščanjem (ko se levodopa počasi sprošča več ur).
It should only be administered with SurePal 10, an injection device specifically developed for use with Omnitrope 10 mg/1.5 ml solution for injection.
Dajati se sme samo z napravo SurePal 10, pripravo za injiciranje, narejeno posebej za uporabo z zdravilom Omnitrope 10 mg/1,5 ml raztopina za injiciranje.
It should only be administered with SurePal 10, an injection device specifically developed for use with Omnitrope 10 mg/1.5 ml solution for injection.
Uporablja se lahko samo z SurePal 10, pripomočku za injiciranje, narejeni posebej za uporabo raztopine za injiciranje Omnitrope 10 mg/1,5 ml.
It should only be administered with SurePal 15, an injection device specifically developed for use with Omnitrope 15 mg/1.5 ml solution for injection.
Dajati se sme samo z injekcijskim peresnikom SurePal 15, pripravo za injiciranje, narejeno posebej za uporabo z zdravilom Omnitrope 15 mg/1,5 ml raztopina za injiciranje.
It should only be administered with SurePal 15, an injection device specifically developed for use with Omnitrope 15 mg/1.5 ml solution for injection.
Uporablja se lahko samo v injekcijskem peresniku SurePal 15, pripomočku za injiciranje, narejenem posebej za uporabo raztopine za injiciranje Omnitrope 15 mg/1,5 ml.
It should only be administered with SurePal 5, an injection device specifically developed for use with Omnitrope 5 mg/1.5 ml solution for injection.
Uporablja se lahko samo z SurePal 5, pripomočku za injiciranje, narejeni posebej za uporabo raztopine za injiciranje Omnitrope 5 mg/1,5 ml.
It should only be given to patients who weigh at least 25 kg.
Daje se lahko samo bolnikom s telesno maso vsaj 25 kg.
It should only be started after the presence of wild-type RAS (KRAS and NRAS genes) has been confirmed by an experienced laboratory using a validated test method.
Uvede se lahko le potem, ko je bila v laboratoriju z izkušnjami na tem področju z uporabo odobrene testne metode potrjena prisotnost divjega tipa RAS (genov KRAS in NRAS).
It should only be used in specialised burns centres, and should not be applied to more than 15% of the
Uporablja se samo v specializiranem centru za opekline, nanese pa se lahko na največ 15 % celotne površine telesa bolnika.
It showed a close temporal relationship and positive rechallenge and dechallenge which support a causal relationship Ganfort PF and Asthma and other asthma-related symptoms including dyspnea and wheezing.
Ugotovljena sta bila tesna časovna povezava ter pozitiven odziv na prenehanje uporabe in ponovno uporabo, kar podpira vzročno povezavo med zdravilom Ganfort PF in astmo ter drugimi simptomi, povezanimi z astmo, vključno z dispnejo in sopenjem.
It slows down the rate at which amprenavir is broken down, increasing the
Učinkuje tako, da upočasni hitrost razgrajevanja amprenavirja in s tem zviša njegove ravni v krvi.
It slows down the rate at which indinavir is broken down, increasing the levels of indinavir in the blood.
Učinkuje tako, da upočasni hitrost razgrajevanja indinavirja in s tem zviša njegove ravni v krvi.
It slows down the rate at which saquinavir is broken down, increasing the levels of saquinavir in the blood.
Upočasni hitrost razgradnje sakvinavirja in s tem zviša njegove ravni v krvi.
It starts to build up in certain cells of the body’s immune system.
Namesto tega se kopiči v določenih celicah imunskega sistema.
it still concentrate.
edijo pri miru; se osredotočijo.
It stimulates the ‘transient receptor potential vanilloid 1’ (TRPV1) receptor which is found in the nerves in the skin that detect pain.
Spodbuja vaniloidni receptor 1 (TRPV1), ki je v živcih na koži, ki zaznavajo bolečino.
It stops a chemical in the body called ‘substance P’ from attaching to the NK1 receptors.
Preprečuje, da bi se kemična snov v telesu, imenovana snov P, vezala na receptorje za NK1.
It suppresses the activity of ‘T cells’, immune system cells that can become involved in organ rejection.
Zavira delovanje limfocitov T, tj. celic imunskega sistema, ki lahko vplivajo na zavrnitev organa.
It takes about 30 minutes to prepare the injection.
Pripravljanje injekcije traja približno 30 minut.
It therefore decided that Esbriet’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Zato sklenil, da so koristi zdravila Esbriet večje od z njim povezanih tveganj, in priporočil izdajo dovoljenja za promet z njim.
It took 5.6 months for the disease to get worse in patients taking Xeloda and cisplatin, and 5.0 months in patients receiving 5-FU and cisplatin.
Pri bolnikih, ki so jemali zdravilo Xeloda in cisplatin je trajalo 5,6 meseca, da se je bolezen poslabšala, pr bolnikih, ki so jemali 5-FU in folno kislino pa 5,0 meseca.
It treats constipation that is caused by medicines for moderate to severe pain called opioids (for example morphine or codeine).
Uporablja se za zdravljenje zaprtja, ki ga povzročajo zdravila za lajšanje zmernih do hudih bolečin, imenovana opioidi (na primer morfin in kodein).
It treats tick infestations and prevents new infestations for up to three weeks.
Zdravi infestacije s klopi in največ tri tedne preprečuje nove infestacije.
It uses the same amorphous aluminium hydroxyphosphate sulphate adjuvant as qHPV vaccine.
Kot adjuvans je uporabljen enak amorfni aluminijev hidroksifosfat sulfat kot v qHPV cepivu.
It was 1.07 in centres with the best control of warfarin therapy (4th quartile with > 73.9% of INR values in the therapeutic range).
V centrih z najboljšo kontrolo varfarinske terapije (4. kvartil z > 73,9 % vrednosti INR v terapevtskem območju) je bilo 1,07.
It was a randomized, double-blind, active controlled, two-treatment, crossover study, comparing Enzepi to standard pancreatic enzyme treatment during
To je bila randomizirana, dvojno slepa, aktivno nadzorovana navzkrižna študija z dvema zdraviloma, v kateri so primerjali zdravilo Enzepi s standardnim zdravilom z encimi trebušne slinavke v dveh obdobjih zdravljenja.
It was also compared with placebo as an add-on to atenolol in 889 patients and as an add-on to amlodipine in 728 patients.
Primerjali so ga tudi s placebom kot dodatkom atenololu pri 889 bolnikih in kot dodatkom amlodipinu pri 728 bolnikih.
It was also decided to introduce to ibandronic acid the same measures taken for other bisphosphonates and denosumab.
Prav tako je sklenil, da bodo za ibandronsko kislino veljali enaki ukrepi kot za ostale difosfonate in denozumab.
It was also effective in children when used with ribavirin, with 46% of the children having responded to treatment at the six-month follow up visit following a year’s treatment.
V kombinaciji z ribavirinom je bilo učinkovito tudi pri otrocih, saj je bilo ob pregledu po šestmesečnem obdobju spremljanja, ki je sledilo enoletnemu zdravljenju, ugotovljeno, da se je na zdravljenje odzvalo 46 % otrok.
It was also independent of age, sex, body surface area, renal and hepatic function, diagnosis and severity of the illness.
Bila je neodvisna tudi od starosti, spola, površine telesa, delovanja ledvic in jeter, diagnoze ter resnosti bolezni.
It was compared with placebo or entacapone (another medicine for Parkinson’s disease).
Primerjali so ga s placebom ali entakaponom (drugim zdravilom za zdravljenje Parkinsonove bolezni).
It was concluded that levetiracetam was not different (non inferior) from placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory Screen Composite score in the per-protocol population.
Ugotovili so, da se zdravilo Levetiracetama pri populaciji po protokolu ne razlikuje (ni manjvredno) od placeba glede spremembe od začetnih vrednosti rezultatov testiranja spomina in pozornosti (Leiter-R Attention and Memory, Memory Screen Composite).
It was demonstrated that the use of a 0.2 micron in-line filter removes visible particles and does not result in an apparent loss of protein or activity.
Dokazano je bilo, da se z uporabo 0,2 mikronskega filtra odstranijo vidni delci in ne pride do očitne izgube beljakovin ali učinkovitosti.
It was found that the early initiation of treatment resulted in a further reduced risk for the development of hepatocellular carcinoma (13.5-fold when initiated prior to the age of 12 months).
Odkrili so, da je zgodnji začetek zdravljenja še bolj zmanjšal tveganje za razvoj hepatocelularnega karcinoma (13,5-krat, če se je zdravljenje začelo pred 12. mesecem starosti).
It was intended that all patients maintained blood phenylalanine levels within a range of 120-360 µmol/l (defined as ≥120 to <360 µmol/l) through monitored dietary intake during the 26-week Study Period.
Namen je bil, da se pri vseh bolnikih vzdržujejo ravni fenilalanina v krvi v razponu 120–360 µmol/l (opredeljeno kot ≥ 120 do < 360 µmol/l) z nadzorovanim vnosom hrane v 26-tedenskem obdobju študije.
It was later confirmed that benefit is limited only to patients with wild-type RAS tumours, rather than patients with mutant RAS tumours.
Kasneje je bilo potrjeno, da so koristi omejene na bolnike z divjim tipom gena RAS v tumorjih, ne pa tudi na bolnike z mutiranim genom RAS.
It was managed during the clinical programme by monitoring laboratory values and the use of a pre-specified management algorithm (see sections 4.3, 4.4, and 5.1).
V kliničnem programu je bila obravnavana z laboratorijskim spremljanjem ravni in predhodno določenim algoritmom obravnave (glejte poglavja 4.3, 4.4 in 5.1).
It was more effective than placebo at preventing death due to disease of the heart or blood vessels or hospitalisation due to worsening heart failure: 24.5% (793 out of 3,241) of patients treated with Ivabradine Anpharm died or were hospitalised for the first time due to worsening heart failure, compared with 28.7% (937 out of 3,264) of patients treated with placebo.
To zdravilo je bilo učinkovitejše od placeba pri preprečevanju smrti zaradi bolezni srca ali ožilja ali hospitalizacije zaradi poslabšanja srčnega popuščanja: 24,5 % (793 od 3 241) bolnikov, zdravljenih z zdravilom Ivabradine Anpharm, je umrlo ali je bilo prvič hospitaliziranih zaradi poslabšanja srčnega popuščanja v primerjavi z 28,7 % (937 od 3 264) bolnikov, ki so bili zdravljeni s placebom.
It was not clearly dose dependent, but most responses were seen at doses of ≥ 200 mg.
Čeprav ni bil povsem očitno odvisen od odmerka, so največ odzivov opazili pri odmerkih ≥ 200 mg.
It was not possible to detect stavudine in cerebrospinal fluid until at least 2 hours after oral administration.
V cerebrospinalnem likvorju je bilo mogoče stavudin odkriti šele najmanj 2 uri po peroralni uporabi.
It was noted that Asian subjects had 1.5 fold increased exposure to lurasidone compared to Caucasian subjects.
Pri osebah azijskega porekla je bila izpostavljenost lurasidonu 1,5-krat večja kot pri belcih.
It was noted that hyponatremia has been observed with similar frequency in the ranolazine (0.09%) and placebo (0.12%) groups in a placebo controlled study.
Ugotovljeno je bilo, da se je v s placebom kontrolirani študiji, hiponatriemija pojavila podobno pogosto v skupini zdravljeni z ranolazinom (0,09%) in placebom (0,12%).
It was observed that the proportion of headache, chills, pyrexia, nausea, vomiting, hypotension, heart rate increase and back pain in children was higher than in adults.
Ugotovili so, da je bil delež glavobola, mrzlice, zvišane telesne temperature, navzee, bruhanja, znižanega krvnega tlaka, zvečanja srčne frekvence in bolečine v hrbtu pri otrocih večji kot pri odraslih.
It was observed that the proportion of headache, fever, heart rate increased and low blood pressure in children was higher than in adults.
Opazili so, da je delež glavobola, vročine, zvečanega srčnega utripa in znižanega krvnega tlaka pri otrocih večji kot pri odraslih.
It will also continue ongoing studies to further analyse the benefit of Strensiq in children from 13 to 18 years of age.
Nadaljevala bo tudi s študijami, s katerimi bo dodatno analizirala koristi zdravila Strensiq pri otrocih, starih od 13 do 18 let.
It will also help to reduce the loss of daily weight gain and mortality associated with PCV2 infection.
Prav tako se uporablja za zmanjšanje izgube dnevnega prirasta telesne mase in umrljivosti, povezanih s to okužbo.
It will also include information on when not to use Multaq, medicines that interact with Multaq, and the need to monitor the function of the liver, lung, heart and kidneys before and during treatment to help manage the risk of severe complications.
Na njej bo navedeno tudi, kdaj se zdravila Multaq ne sme uporabljati, zdravila, ki medsebojno delujejo z zdravilom Multaq, ter informacije o tem, da je treba preverjati delovanje jeter, pljuč, srca in ledvic pred zdravljenjem in med njim, da bi tako preprečili tveganje hudih zapletov.
It will also provide an information pack for patients to explain the medicine’s side effects, remind them of the need for adequate calcium and vitamin D supplementation, and when patients should contact their doctor.
Prav tako bo pripravila informativno gradivo za bolnike, v katerem bodo razloženi neželeni učinki, poudarjena potreba zadostnega nadomeščanja kalcija in vitamina D ter navodilo, kdaj morajo poiskati pomoč zdravnika.
It will also supply all doctors in each Member State who prescribe Tysabri with an educational pack that includes information on the safety of Tysabri, including information on which patients may be at a higher or lower risk of PML.
Prav tako bo za vse zdravnike v posameznih državah članicah, ki predpisujejo zdravilo Tysabri, pripravila izobraževalno gradivo z vsemi informacijami o varnosti zdravila Tysabri, vključno z informacijami o tem, pri katerih bolnikih obstaja večje ali manjše tveganje, da nastopi PML.
It will also supply cards for patients to ensure that all appropriate safety measures are taken by each patient.
Prav tako bo izdala kartice za bolnike, da bi tako zagotovila, da vsak bolnik izpolnjuje vse ustrezne varnostne ukrepe.
It will also supply cards for patients to ensure that all appropriate safety measures have been taken by each patient.
Prav tako bo priskrbela kartice za bolnike, s pomočjo katerih bo lahko vsak bolnik preveril, ali je upošteval vse ustrezne varnostne ukrepe.
It will be administered into a vein by a health care professional.
Zdravilo vam bo zdravstveno osebje dalo v obliki infuzije v veno.
It will be dripped onto the tissue in very small amounts or sprayed in short bursts (0.1-0.2 ml), to produce a thin, even layer.
Zdravilo se nakapa na tkivo v majhni količini ali razprši v kratkih razprških (0,1–0,2 ml), da nastane tanek, enakomeren sloj.
It will be given slowly over a period of 1 hour.
Infuzijo boste prejemali počasi, trajala bo 1 uro.
It will be injected into a muscle.
Cepivo se injicira v mišico.